Overview

Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin concurrent IMRT for locally advanced cervical cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking University Third Hospital
Treatments:
Antibodies